Literature DB >> 32487659

A Phase II Study of Neoadjuvant Chemotherapy Followed by Extended Field Concurrent Chemoradiotherapy for Para-aortic Lymph Node Positive Cervical Cancer.

Yuko Shimoji1, Yutaka Nagai1, Takafumi Toita2, Takuro Ariga2, Joichi Heianna2, Tadaharu Nakasone1, Yusuke Taira1, Yoshihisa Arakaki1, Tomoko Nakamoto1, Takuma Ooyama1, Wataru Kudaka1, Itomi Kaneshima1, Kumiko Nishihira1, Keiko Mekaru1, Yoichi Aoki3.   

Abstract

BACKGROUND/AIM: We conducted a phase II study of neoadjuvant chemotherapy followed by extended field concurrent chemoradiotherapy in patients with cervical cancer with para-aortic node metastasis. PATIENTS AND METHODS: Thirty-seven women with stage IB1-IVA cervical cancer were enrolled.
RESULTS: The median age was 52 years. Thirty-four patients other than 3 progressive disease, proceeded to extended field concurrent chemoradiotherapy. The 3-year overall survival and progression-free survival rates were 70.1% and 48.5%, respectively. The 3-year overall survival according to stages was significantly worse in stage IIIB. Twelve of the 17 patients with stage IIIB died of the disease.
CONCLUSION: Neoadjuvant chemotherapy followed by extended field concurrent chemoradiotherapy may improve the prognosis of patients with stages IB and II cervical cancer with positive para-aortic node. However, new strategies should be investigated to improve a poor prognosis in stage IIIB disease with positive para-aortic node. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Cervical cancer; extended-field concurrent chemoradiotherapy; neoadjuvant chemotherapy; para-aortic node metastasis; phase II study

Year:  2020        PMID: 32487659     DOI: 10.21873/anticanres.14346

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  In vivo Multi-scale Photoacoustic Imaging Guided Photothermal Therapy of Cervical Cancer based on Customized Laser System and Targeted Nanoparticles.

Authors:  Ting Qiu; Yintao Lan; Zuwu Wei; Yanfen Zhang; Yanping Lin; Chenggong Tu; Guangjuan Mao; Lingmin Zhang; Bin Yang; Jian Zhang
Journal:  Int J Nanomedicine       Date:  2021-04-15

2.  Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.

Authors:  Jing Li; Hua Liu; Ya Li; Jian Li; Lifei Shen; Wenqing Long; Chenmin Yang; Haoping Xu; Wenqi Xi; Rong Cai; Weiwei Feng
Journal:  Trials       Date:  2022-01-10       Impact factor: 2.279

Review 3.  Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.

Authors:  Fengying Qin; Huiting Pang; Tao Yu; Yahong Luo; Yue Dong
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.